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Summary
Mesenchymal stromal cells (MSCs) have been successfully used for the treatment of
steroid-resistant graft-versus-host-disease (GvHD). However, the lack of early pre-
dictors of clinical responses impacts on the time at which to add further treatment
and consequently the design of informative clinical trials. Here, we present the UK
experience of one of the largest cohorts of GvHD patients undergoing MSC infu-
sions so far reported. We show that clinical responses assessed as early as 1 week
after MSC infusion predict patients’ overall survival. In our cohort, cell dose,
patients’ age and type of organ involvement are crucial factors associated with clini-
cal responses.
Keywords: cellular therapies, GvHD, mesenchymal cells, clinical research,
stromal cells.
Acute graft-versus-host disease (aGvHD) is a life-threatening
complication of allogeneic haematopoietic stem cell trans-
plantation (HSCT) and one of the major factors limiting its
success (Ferrara et al, 2009). Currently there is no established
strategy to treat steroid-resistance in aGvHD patients, which
is associated with a dismal prognosis. Mesenchymal stromal
cells (MSCs) are a heterogeneous population of cells with
potent immunosuppressive activity (Marigo & Dazzi, 2011).
They have been extensively tested as a salvage option to treat
steroid-resistant aGvHD patients and convincingly shown to
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improve the survival of responding patients (Le Blanc et al,
2008; von Dalowski et al, 2016). Despite these encouraging
results, there is still a pressing need to identify reliable factors
that can be used as early predictors of treatment outcome, to
identify those patients more likely to respond and the most
effective administration regimen. An improved understand-
ing of these issues would significantly optimize MSC treat-
ment and help clinicians to better define the role of MSCs in
the armamentarium of GvHD therapy.
In this study, we present the retrospective analysis of a
cohort of 60 steroid-resistant aGvHD patients treated with
bone marrow-derived MSCs at several Centres in the UK
between May 2008 and December 2014. MSCs were manu-
factured at Imperial College Healthcare NHS Trust and
administered for compassionate use [according to Regulation
(EC) No 1394/2007]. aGvHD was biopsy proven in 45
patients, whilst in the remaining patients the diagnosis was
based on clinical features after excluding alternative causes.
Patients were considered to be steroid-refractory when they
failed to respond to high-dose methylprednisolone (≥2 mg/
kg body-weight) after 6 days or if GvHD progressed after
3 days. Detailed demographics of patients are summarized in
Table SI. Response to MSC treatment was assessed 1 week
after administration. In accordance with previous experiences
(Resnick et al, 2013; von Dalowski et al, 2016), responses
were defined as complete (CR) in the event of complete dis-
appearance of all symptoms and signs of the disease in all
organs or partial (PR) when an improvement of at least 50%
was observed in at least one organ affected by aGvHD. Stable
or progressive disease were classified as no response (NR).
Informed consent was obtained from all patients in accor-
dance with the local ethics committee requirements. Data
were analysed as of last data collection in June 2015. Addi-
tional details are available in the Data S1.
The median time from HSCT to MSC treatment was
62 days (range: 12–929 days), the median time from GvHD
diagnosis to MSCs was 60 days (range: 11–905 days). Thirty-
four patients received 1 MSC dose, while 16, 6 and 1 patients
were treated with 2, 3 and 4 doses, respectively. The median
dose of MSCs was 26 9 106/kg body-weight per infusion
(range: 06–156 9 106/kg body-weight). No significant
adverse reactions were observed.
We selected to assess clinical responses 1 week after the
first dose to obtain an early predictor of clinical outcome.
Overall, 32 patients (53%) responded to MSCs, with 1
(16%) and 31 (516%) patients achieving CR or PR, respec-
tively. Amongst patients who received multiples doses, in
most cases subsequent doses did not change the type of
response obtained after the first dose, with the exception of
two patients. One patient responded to the first dose with a
PR, received a second one but relapsed a week after. The sec-
ond patient achieved PR after the first dose and CR after the
second.
The estimated median overall survival (OS) of all patients
was 104 days [95% confidence interval (CI): 0–215 days]
(Fig 1A), with a median follow-up of 741 days for patients
alive (range 461–2521 days). Response to MSCs had a major
impact on OS, with a longer estimated OS in responding
patients compared with non-responders (Fig 1B). We evalu-
ated the association between OS and gender, age, pre-MSC
therapy, interval from HSCT or aGvHD diagnosis to MSC
treatment, grade of aGvHD, organ involved and the response
to MSCs. By using both univariate and multivariate analysis,
we found that the presence of any kind of response (CR or
PR) assessed after 1 week from the first MSC infusion and
the organ affected by GvHD were strong predictors for sur-
vival (Table SII).
We investigated whether we could identify factors associ-
ated with clinical responses. We found that patient gender,
pre-MSC therapy, interval from HSCT or aGvHD diagnosis
to MSC treatment and grade of aGvHD did not affect clini-
cal responses (Table SII). Conversely, organ involvement, age
at HSCT and the dose of MSC infused were significantly
associated with the response rate to MSC infusions
(Table SII). The proportion of responders was 67% (n = 28)
amongst patients with involvement of gut, skin or both, but
only 22% (n = 4) amongst those with liver involvement
(alone or in combination with skin and/or gut). Patients
Fig 1. Probability of survival following MSC treatment. (A) Probability of survival of the whole cohort of patients. (B) Probability of survival of
responders and non-responders. log-rank test, P < 0.0001; hazard ratio: 02. Median survival in responders was not reached, while it was 20 days
(95% CI 11–29 days) in non-responders. Overall survival estimates start from mesenchymal stromal cell (MSC) infusion.
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younger than 20 years fared better, with 88% (n = 15) of
them responding to MSCs. Conversely, only 30% (n = 7)
and 43% (n = 6) of those aged 20–50 years or older than
50 years responded, respectively. Lastly, higher response rates
(77%, n = 13) were observed in patients receiving MSC
doses >30 9 106/kg compared with patients receiving 15–
30 9 106/kg (56%, n = 18) or <15 9 106/kg (9%, n = 1)
(Table SII). All these 3 factors remained significant in multi-
variate logistic regression analysis (Table I).
Our data demonstrate that clinical responses at 1 week
after MSC infusion can be considered an early predictor of
clinical outcome. Such an approach is in contrast with the
current practice of evaluating responses at 28 days (Resnick
et al, 2013; von Dalowski et al, 2016) and might understate
the rate and magnitude of clinical responses. In fact, the rate
of CR in our cohort is very low compared to other studies
(Le Blanc et al, 2008; Sanchez-Guijo et al, 2014). In our
study we could not document whether our responding
patients eventually achieved CR at later time points, because
we were unable to retrieve consistent data after day 7. How-
ever, the obtainment of any kind of response (either PR or
CR) was sufficient to affect OS. This is consistent with previ-
ous studies in patients who, like ours, were refractory to sev-
eral lines of treatment (Resnick et al, 2013; Kurtzberg et al,
2014; von Dalowski et al, 2016; Muroi et al, 2016; Dotoli
et al, 2017; Servais et al, 2018). In contrast, other groups
have reported that, when MSCs were administered soon after
steroids, only CR are associated with improved OS (Le Blanc
et al, 2008; Kebriaei et al, 2009; Sanchez-Guijo et al, 2014).
The results of a very recent study seem to explain the differ-
ences and reconcile the inconsistency. Although patients who
have been heavily pre-treated before MSC infusion achieve
CR less frequently than those who receive MSCs as second
line, the OS of the two groups does not differ, regardless of
the response achieved (CR or PR) (Bader et al, 2018).
An early assessment of the response has therefore the
advantage of providing crucial information to enable prompt
management of alternative approaches both in clinical prac-
tice and in the context of clinical trials.
Because of the retrospective nature of the study, the dose
range of MSCs was large, thereby allowing us to identify a
significant association between higher doses and a positive
response. This observation is in contrast with other reports
(Ball et al, 2013; von Dalowski et al, 2016) but the discrep-
ancy could be ascribed to the fact that, in those studies, the
dose ranges were too narrow and the number of patients too
small to identify any correlation between response and dose.
Our data have been confirmed by a recent multicentre
prospective study, in which patients who received doses of
3–4x106/kg body-weight had better responses and longer sur-
vival rates than those who received 1–2 9 106/kg body-
weight (Servais et al, 2018). Our study confirms that patient
age and the affected organ significantly affect responses to
MSCs (Resnick et al, 2013; Sanchez-Guijo et al, 2014). In
contrast, we could not find any association between GvHD
grade (Resnick et al, 2013) or time from GvHD to MSCs
(Ball et al, 2013) and response to MSCs.
In summary, our data strengthen the role of the MSC
recipient (Galleu et al, 2017) rather than the one of MSC
donor or source in predicting clinical responses. This obser-
vation is supported by the findings of other groups (Le Blanc
et al, 2008; Kebriaei et al, 2009; von Dalowski et al, 2016),
whereby when MSCs from the same donor were used to treat
several patients, only a proportion of them achieved remis-
sion. Such a perspective suggests that the variability in MSC
manufacturing bears a limited impact (Trento et al, 2018).
Overall, these findings provide an innovative angle that could
be harnessed to improve the complex design of future clini-
cal studies for the treatment of GvHD with MSCs.
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